Drug Profile
Icrucumab - Eli Lilly and Company
Alternative Names: 18F1; IMC-18F1; LY 3012212; Monoclonal-antibody-18F1Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator ImClone Systems
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Urogenital cancer
Most Recent Events
- 30 Jul 2021 Discontinued - Phase-II for Breast cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada and USA (IV) before July 2021 (Eli Lilly and Company pipeline, July 2021)
- 31 Aug 2018 Icrucumab is still in phase II trials for Breast cancer in Canada
- 01 Jul 2017 Eli Lilly completes a phase II trial in Breast cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second line therapy or greater) in the USA and Canada (NCT01234402)